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In late 2009 transplant organizations recommended
that kidney recipients be vaccinated for pandemic H1N1
influenza (pH1N1); however, the vaccine efficacy was
unknown. We had offered a monovalent non-adjuvanted
pH1N1 vaccine to transplant recipients. Here we compared
the pre- and post-vaccination seroresponses of 151
transplant recipients to that of 71 hemodialysis patients
and 30 healthy controls. Baseline seroprotection was
similar between groups but was significantly different at
1 month (44, 56, and 87%, respectively). Seroconversion was
significantly less common for transplant recipients (32%)
than dialysis patients (45%) and healthy controls (77%).
After adjusting for age and gender, dialysis patients were
significantly more likely (2.7-fold) to achieve new
seroprotection than transplant recipients. The likelihood
of seroprotection in transplant recipients was significantly
reduced by mycophenolate use (adjusted odds ratio 0.24), in
a dose-dependent manner, and by reduced eGFR (adjusted
odds ratio 0.16 for worst to best). Seroprotection and
geometric mean antibody titers increased substantially in 49
transplant recipients who subsequently received the 2010
seasonal influenza vaccine. Thus, patients requiring renal
replacement therapy had reduced seroresponses to
vaccination with the monovalent vaccine compared with
healthy controls. Transplant recipient responses were further
reduced if they were receiving mycophenolate or had
significantly lower graft function.
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An influenza pandemic, generated by a novel strain of
influenza A (pH1N1), was declared by the World Health
Organization in June 2009.1 Low levels (o20%) of preexisting
seroprotective antibody titers in people from most countries,
including Australia, against pH1N1 were due to antigenic
differences between the pre-pandemic seasonal H1N1 strains
previously circulating in humans and the pH1N1 virus, which
emerged from pigs.2 As a result of this antigenic difference,
seasonal influenza trivalent vaccines produced before the 2009
pandemic did not result in significant rates of seroprotection
against pH1N1.3–5 To address this, monovalent pH1N1
vaccines were rapidly developed and were shown to be highly
effective in healthy volunteers.6–8 In September 2009, interna-
tional transplant societies recommended that solid organ
transplant recipients receive the monovalent vaccine along
with their family members and close contacts.9 No data on the
efficacy of the monovalent vaccines in kidney transplant
recipients were available at that time.
Kidney transplant recipients in the era of modern
immunosuppressive agents have typically demonstrated a
reduced capacity to generate seroprotective antibody titers
against H1N1 after seasonal trivalent influenza vaccination
compared with healthy controls.10–14 Mycophenolate appears
to be particularly effective at reducing rates of seroprotec-
tion.11,13–15 Although seroresponses are reduced in kidney
transplant recipients, seroprotection is achieved in a
significant percentage, and this may be increased in centers
that encourage annual vaccination.13 As such, the seasonal
trivalent influenza vaccination is recommended for kidney
transplant recipients from 3 to 6 months post transplant.16
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We accepted the advice to immunize our kidney transplant
recipients against pH1N1 in late 2009. Although three recent
studies have reported impaired seroresponses to adjuvanted
pH1N1 vaccines in kidney transplant recipients,17–19 we now
present the first data regarding seroresponses to a monovalent
non-adjuvanted pH1N1 vaccine in a larger cohort of kidney
transplant recipients. Their responses are compared with a
hemodialysis patient population and healthy controls with a
focus on those kidney transplant recipients at greatest risk
of pH1N1 infection on the basis of having no baseline
seroprotection. The overall low baseline seroprotection rates
in the community provided the opportunity to test the
hypothesis that there is a stepwise hierarchy of seroresponses
from healthy controls with best responses, through hemodia-
lysis patients with intermediate responses, to kidney transplant
recipients with the poorest responses, and furthermore that
transplant recipients’ responses are modulated by renal
function and mycophenolate use. We also offer support to
the recommendation of seasonal influenza vaccination in
transplant recipients by demonstrating a boosting effect in
those who received the 2010 influenza vaccine after receiving
the 2009 monovalent pH1N1 vaccine.
RESULTS
Participants
In all, 526 kidney transplant recipients were approached for
inclusion in the study (Figure 1). Of these, 287 patients
were excluded from further participation: 75/526 (14.3%)
declined to participate, 10/526 (1.9%) were deemed un-
suitable because of active illness or transplantation within
21 days, 105/526 (20.0%) did not respond to phone or postal
invitations for vaccination, and 97/526 (18.4%) received
vaccination from their family doctor. Of the 526 subjects, 239
(45%) received the monovalent pH1N1 vaccine at our center
and had pre-vaccination pH1N1 serology performed. Pre-
vaccination and 1 month post-vaccination serology were
available in 151/239 (63.2% of the cohort vaccinated at our
center).
In all, 82 hemodialysis patients attending two satellite
hemodialysis facilities had pre-vaccination serology and
received the monovalent pH1N1 vaccine (Figure 1); 71 had
1 month post-vaccination serology. Pre- and post-vaccina-
tion sera were available from 30 healthy control participants.
Basic demographics of the kidney transplant and hemo-
dialysis patients are presented in Table 1. The kidney
transplant recipients were younger, with a greater proportion
of female recipients compared with the hemodialysis patients.
Glomerulonephritis was the most common cause of end-
stage kidney failure in the transplant recipients, whereas
diabetes mellitus was more common in the hemodialysis
patients. The healthy controls were significantly younger on
average and had a higher proportion of female participants
than both the renal replacement groups. They had no
significant medical conditions.
Baseline seroprotection
Pre-vaccination antibody titers were available in 239 kidney
transplant recipients, 82 hemodialysis patients, and 30
healthy controls. The baseline level of seroprotection was
not different between the three groups, with 35 (14.6%)
kidney transplant recipients, 13 (15.9%) hemodialysis
patients, and 3 (10%) healthy controls with titers X40
(P¼ 0.74) (Table 2).
Seroresponses
Pre- and post-vaccination serology was available in 151
kidney transplant recipients. In all, 20/151 (13%) had
seroprotection at baseline, and this increased to 66/151
Kidney transplant recipients
n=526
Vaccinated at transplant center
and had pre-vaccination serology
n=239
Vaccinated at transplant center and
had pre- and post-vaccination
serology
n=151
Vaccinated at dialysis centers and
had pre- and post-vaccination
serology
n=71
Vaccinated and had pre- and
post-vaccination serology
n=30
Vaccinated at dialysis centers and
had pre-vaccination serology
n=82
Hemodialysis patients
n=82
Healthy controls
n=30
Excluded n=287
Excluded n=88 Excluded n=11
Declined vaccination = 75
Did not complete post-
vaccination serology
Did not complete post-
vaccination serology
Unsuitable = 10
Not contactable = 105
Vaccinated elsewhere = 97
Figure 1 | Study design. Participants were included in the complete analyses of the study if they received vaccination and had both pre-
and post-vaccination serology performed. Baseline seroprotection levels were determined using serology from all participants who had
blood taken before vaccination.
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(44%) at 1 month post vaccination (Table 2). Of the 71
hemodialysis patients who completed pre- and post-vaccina-
tion serology, there was a similar level of baseline seroprotec-
tion (16%), but a greater level of seroprotection at 1 month
(56%) (Table 2). The healthy controls had the largest
response, with baseline and 1 month seroprotective rates of
10 and 87%, respectively (Table 2). Seroprotective titers at
1 month were significantly different between groups
(Po0.001) (Table 2). Similarly, geometric mean antibody
titers were not different at baseline (kidney transplant¼ 9,
hemodialysis¼ 11, and healthy controls¼ 8), but were signi-
ficantly different at 1 month (kidney transplant¼ 26.8,
hemodialysis patients¼ 53.1, and healthy controls¼ 121.3;
Po0.001) (Table 2). Finally, seroconversion (titerX40 and a
X4-fold increase in titer) was significantly less common in
transplant recipients compared with hemodialysis patients
and healthy controls (31.8, 45.1, and 77%, respectively;
Po0.001) (Table 2).
In those without seroprotection at baseline, the same
trend was observed with transplant recipients having signi-
ficantly lower seroprotection and seroconversion rates with
lower geometric mean antibody titers at 1 month compared
with hemodialysis patients and healthy controls (Table 2).
After adjustment for age and gender, hemodialysis patients
were more than two times as likely (adjusted odds ratio
(aOR) 2.68, 95% confidence interval (CI) 1.31–5.52,
P¼ 0.007) and healthy controls six times as likely to achieve
seroprotection (aOR 5.84, CI 1.79–19.06, P¼ 0.003) than
transplant recipients (Table 3). Advancing age was associated
with a reduced likelihood of achieving new seroprotection
(Table 3). Cause of end-stage renal failure was not associated
with achieving seroprotection.
Transplant recipients
The demographic details, comorbidities, and immuno-
suppressive regimens are summarized in Table 4. The median
time since transplant was 3.7 years (range 0.1–27.9 years).
Most (137 (90.7%)) were primary grafts, whereas 11 (9.3%)
and 3 (2%) were second and third grafts, respectively. The
majority of recipients (90%) were receiving a calcineurin
inhibitor (65% tacrolimus and 35% cyclosporine). Myco-
phenolate was used by 82%, whereas 64% were taking
prednisolone. Median transplant function was 49ml/min per
1.73m2 with 9, 52, and 39% with an estimated glomerular
filtration (eGFR) of 0–30, 31–60, and X60ml/min per
1.73m2, respectively. In total, 68 (45%) patients had received
the 2009 seasonal trivalent influenza vaccine.
Univariate and multivariate analyses of the transplant
cohort without baseline seroprotection (n¼ 131) was under-
taken to determine which factors influenced the likelihood of
new seroprotection (Table 5). Mycophenolate use was
independently associated with a 76% reduced likelihood of
achieving seroprotection (aOR 0.24, CI 0.07–0.79, P¼ 0.02)
(Table 5 and Figure 2a). A dose effect of mycophenolate on
response rates was apparent after adjusting for recipient age
and gender, transplant duration, calcineurin inhibitor use,
prednisolone use, and rituximab use. Patients on X2 g per
Table 1 | Characteristics of renal replacement study groups
Variable
Kidney
transplant
Hemo-
dialysis
Healthy
control P-value
Male gender 84 (55.6) 47 (66.2) 10 (33.3) 0.01
Age (years) 51.2±12.6 62.6±12.8 32.6±13.1 o0.001
Primary kidney disease o0.001
Glomerulonephritis 84 (56) 17 (24)
Diabetes mellitus 21 (14) 31 (44)
Hypertension/ischemic 8 (5) 3 (4)
ADPCKD 20 (13) 4 (6)
Reflux nephropathy 18 (12) 4 (6)
Unknown 4 (3) 12 (17)
Abbreviations: ADPCKD, autosomal dominant polycystic kidney disease; ANOVA,
analysis of variance.
Data presented are means±1 s.d. or number (percentage). P-values relate to
comparison between groups by ANOVA.
Table 2 | Anti-pH1N1 serology at baseline and 1 month after
vaccination
All
KTR,
n=151
HDP,
n=71
HC,
n=30 P-value*
Seroprotection, n (%)
Baseline 20 (13.2) 11 (15.5) 3 (10) 0.75
1 month 66 (43.7) 40 (56.3) 26 (86.7) o0.001
Geometric mean
Baseline 9.3 11.1 7.8 0.21
1 month 26.8 53.1 121.3 o0.001
Seroconversion, n (%) 48 (31.8) 32 (45.1) 23 (77) o0.001
No baseline
seroprotection
KTR,
n=131
HDP,
n=60
HC,
n=27
P-value*
Seroprotection, n (%)
1 month 47 (35.9) 29 (48.3) 23 (90) o0.001
Geometric mean
Baseline 7.1 7.3 5.4 0.01
1 month 21.8 40.9 108.9 o0.001
Seroconversion, n (%) 47 (35.9) 29 (48.3) 23 (85) o0.001
Abbreviations: ANOVA, analysis of variance; HC, healthy controls; HDP, hemodialysis
patients; KTR, kidney transplant recipients; pH1N1, pandemic H1N1 influenza.
*P-value for comparison across the three groups by the w2 test for seroprotection
and seroconversion and ANOVA for geometric means.
Table 3 | Predictors of achieving seroprotection
Univariate Multivariate
Parameter OR 95% CI P-value aOR 95% CI P-value
Group
Kidney transplant 1.0 — — 1.0 — —
Hemodialysis 1.67 0.90–3.1 0.10 2.68 1.31–5.52 0.007
Healthy controls 10.28 3.35–31.5 o0.001 5.84 1.79–19.06 0.003
Age (per 10 year
increase)
0.69 0.57–0.84 o0.001 0.69 0.54–0.89 0.004
Female gender 1.21 0.71–2.07 0.48 0.98 0.54–1.75 0.93
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
214 Kidney International (2012) 82, 212–219
or ig ina l a r t i c l e WR Mulley et al.: pH1N1 vaccination in kidney transplant recipients
day were significantly less likely to achieve seroprotection
than those on o2 g per day and those taking no myco-
phenolate (20, 34, and 50%, respectively, P¼ 0.026 for trend)
(Figure 3).
The use of other immunosuppressive agents, including
prednisolone and calcineurin inhibitors, did not inde-
pendently predict failure to achieve seroprotection; how-
ever, only 1 of 10 patients who had received rituximab
achieved seroprotection, suggesting reduced de novo antibody
responses with its use. The patient who did achieve sero-
protection received rituximab 3.5 years prior and had normal
B-cell counts at vaccination.
There was an incremental decline in the likelihood of
achieving seroprotection with declining transplant function.
Patients with an eGFR o30ml/min per 1.73m2 were
significantly less likely to achieve seroprotection compared with
those with an eGFRX60ml/min per 1.73m2 (OR 0.16, 95% CI
0.03–0.88, P¼ 0.04; Table 5 and Figure 2b). Advancing age per
10-year increment (aOR 0.70, CI 0.49–0.996, P¼ 0.047) and
shorter transplant duration (o6 vs.X6 months) (aOR 0.10, CI
0.01–0.86, P¼ 0.04) were also associated with a reduced
likelihood of achieving seroprotection (Table 5).
Boosting effect of the 2010 trivalent influenza vaccine
Of the 151 transplant recipients, 49 (32.4%) received the
2010 seasonal trivalent influenza vaccine, which included
antigens specific to the 2009 pH1N1 virus and had their
antibody titers against pH1N1 repeated. This subset of
patients was similar to the group as a whole. Their mean age
was 55.3±10.7 years, 59% were men, and 61% had
glomerulonephritis as the cause of their end-stage kidney
failure. Most (90%) were primary grafts, and the median
transplant duration was 4.9 years (range 0.13–22 years). Most
were on calcineurin inhibitors (88%) and mycophenolate
(80%), whereas 71% were taking prednisolone. The mean
eGFR of this group was 49.3ml/min per 1.73m2 (range
23–92.3ml/min per 1.73m2). The median time between the
two vaccines was 7.4 months (range 3.3–10.5 months).
Seroprotective antibody titers rose in a stepwise manner from
16.3% before the 2009 pH1N1 monovalent vaccine to 34.7%
1 month post vaccination, increasing further to 53.1% after
the 2010 seasonal influenza trivalent vaccine. In addition, the
geometric mean antibody titers increased from 9.3 before
vaccination to 20.3 after the 2009 monovalent vaccine and
further to 31.0 after the 2010 trivalent vaccine.
Safety. No significant adverse events were reported by
those undergoing vaccination; in particular, no patient
required admission or had a hypersensitivity response related
to the vaccine.
DISCUSSION
The major findings of this study were that patients requiring
renal replacement therapy either in the form of hemodialysis
Table 4 | Kidney transplant recipient characteristics
Characteristics of KTRs included (n=151)
Previous grafts: none 137 (90.7)
One 11 (7.3)
Two 3 (2.0)
Tx duration (years) 3.7 (0.1–27.9)
Medications
Tacrolimus 89 (58.9)
Cyclosporine 47 (31.1)
Mycophenolate 123 (81.5)
Azathioprine 24 (15.9)
Prednisolone 96 (63.6)
mTORi 12 (8.0)
Rituximab 10 (6.6)
eGFR (ml/min per 1.73m2) 49.7 (8.9–91.7)
eGFR group
460ml/min per 1.73m2 59 (39)
30–60ml/min per 1.73m2 78 (52)
o30ml/min per 1.73m2 14 (9)
Received 2009 SV 68 (45)
Abbreviations: eGFR, estimated glomerular filtration rate; KTR, kidney transplant
recipients; mTORi, mammalian target of rapamycin inhibitor; SV, seasonal influenza
vaccine; Tx, transplant.
Data presented median (range) or number (percentage).
Table 5 | Factors associated with increased likelihood of seroprotection in kidney transplant recipients without baseline
seroprotection (n=131)
Univariate Multivariate
Parameter OR 95% CI P-value aOR 95% CI P-value
Age (per 10 year increase) 0.73 0.54–1.00 0.05 0.70 0.49–0.996 0.047
Female gender 1.07 0.52–2.18 0.86 0.69 0.53–2.63 0.69
Kidney function
eGFR 460ml/min per 1.73m2 1.0 — — 1.0 — —
eGFR 30–60ml/min per 1.73m2 0.64 0.30–1.39 0.26 0.67 0.27–1.55 0.34
eGFR o30ml/min per 1.73m2 0.20 0.04–1.01 0.052 0.16 0.03–0.88 0.04
CNI vs. no CNI 1.54 0.39–6.12 0.53 4.31 0.76–24.6 0.10
Mycophenolate vs. no mycophenolate 0.35 0.14–0.89 0.03 0.24 0.07–0.79 0.02
Rituximab vs. no rituximab 0.18 0.02–1.48 0.11 0.16 0.02–1.40 0.10
Prednisolone vs. no prednisolone 1.09 0.52–2.28 0.83 1.59 0.67–3.76 0.29
Transplant duration o6 vs. X6months 0.96 0.89–1.03 0.26 0.10 0.01–0.86 0.04
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; OR, odds ratio.
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or a kidney transplant had reduced seroresponses to
vaccination with the monovalent vaccine compared with
healthy controls. Transplant recipient responses were further
reduced if the patient was receiving mycophenolate as part of
their immunosuppressive regimen or had significantly lower
graft function (eGFR o30ml/min per 1.73m2).
Responses to vaccination such as influenza20,21 and
hepatitis B (reviewed in Edey et al.22) have previously been
reported to be diminished in dialysis patients, whereas
studies in kidney transplant recipients have demonstrated
impaired responses to influenza vaccination in the era of
tacrolimus- and mycophenolate-based immunosuppressive
regimens.10–14 The adjuvanted and non-adjuvanted mono-
valent vaccines developed in response to the 2009 H1N1
pandemic resulted in excellent seroresponses in healthy
controls, with approximately 90% achieving seroprotection
post vaccination6–8,23 These rates are consistent with the
healthy controls in our study.
Two recent publications describe seroresponses to differ-
ent adjuvanted monovalent vaccine preparations for pH1N1
in dialysis patients. Seroconversion was almost identical (64.2
and 64.1%) in both studies after a single dose.20,21 Although
not clearly stated in either study, baseline seroprotection
levels appear to be o30%, giving an increment after
vaccination of approximately 30%, which was significantly
less than that for healthy controls. Our observations using a
non-adjuvanted preparation are in keeping with these
studies, with an increment in seroprotection of 39.8% to a
total of 56.3%. The combination of this study and those of
Dikow and Labriola suggest that hemodialysis patients have
significantly impaired responses to pH1N1 vaccination at
approximately half that of healthy controls. An improved
response rate may be achieved by booster dosing, however,
with Dikow et al.20 demonstrating a 24% greater seroprotec-
tion rate in patients administered a second dose of the
vaccine 21 days after the first.
Previous studies of trivalent seasonal influenza vaccination
in kidney transplant recipients describe seroresponses against
pre-pandemic seasonal H1N1 ranging from very poor to
equivalent to healthy controls.10–15 Most of these studies have
examined single-dose vaccination. Seroprotection post vac-
cination is a commonly reported efficacy outcome; however,
this is dependent to a large extent on pre-vaccination
seroprotection levels. For example, post-vaccination seropro-
tection in the study by Scharpe et al.13 was 92.7%, which
exceeded that of the healthy controls (70.7%); however,
baseline seroprotection was already evident in 78.2% of
transplant recipients (as a result of an annual vaccination
policy) compared with 25% of controls, making comparisons
of efficacy difficult. Interestingly, seroconversion was similar
for kidney transplant recipients and healthy controls. In this
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Figure 2 |Reverse cumulative distribution curve of antibody
titers in kidney transplant recipients. (a) Patients taking
mycophenolate had a lower rate of seroprotection post
vaccination compared with those not taking mycophenolate
despite a similar pre-vaccination seroprotection rate. Sero-
protection is defined as having an antibody titer of X40 (gray
dotted vertical line). (b) Post-vaccination seroprotection was
modified by renal function, with patients with the lowest
estimated glomerular filtration (eGFR) achieving the lowest rate of
seroprotection despite similar pre-vaccination seroprotection
rates. Seroprotection is defined as having an antibody titer of
X40 (gray dotted vertical line). HAI, hemagglutination inhibition
assay; MV, monovalent vaccine.
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Figure 3 |Dose effect of mycophenolate on likelihood of
achieving new seroprotection. Patients taking higher doses of
mycophenolate (X2 g per day) achieved a significantly lower rate
of seroprotection compared with those ono2 g per day or on no
mycophenolate after adjustment. CKD, chronic kidney disease.
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study, the absence of significant baseline seroprotection
meant that responses to vaccination could be more clearly
assessed.
Most previous studies comparing vaccination outcomes
in kidney transplant recipients and healthy controls have
demonstrated significantly lower seroresponses and geo-
metric mean antibody titers in transplant recipients.10–12,14,15
Previous studies had not compared seroresponses of
kidney transplant recipients with those of hemodialysis
patients; however, two recent studies using adjuvanted
pH1N1 vaccines have now done so.18,19 The first found no
statistically significant difference between groups but may
have been limited by a small sample size,19 whereas the
second study with larger numbers described statistically
significant differences in response rates, being greatest for
healthy controls, less for dialysis patients, and least for
transplant recipients.18 We demonstrate the same trend using
a non-adjuvanted vaccine wherein the inferior response rates
in kidney transplant recipients retained significance after
controlling for age and gender. This difference in responses is
likely due to the use of immunosuppressive medications and
in particular mycophenolate.
After controlling for other immunosuppressive medica-
tion use, age, gender, and transplant duration, treatment with
mycophenolate reduced the likelihood of achieving sero-
protection in the transplant recipients without baseline
seroprotection by 76%. Furthermore, after adjusting for the
above potential confounding factors, there was a statistically
significant dose effect seen in those receiving mycophenolate.
Previous studies have reported this phenomenon to varying
degrees.12–15 Smith et al.14 reported no seroconversion to
influenza A in patients taking mycophenolate who were given
the seasonal influenza vaccine. Salles et al.15 demonstrated a
50% lower seroconversion rate after influenza A vaccination
in transplant recipients taking mycophenolate compared with
those taking azathioprine. Scharpe et al.13 found a similar
reduction in seroprotection in kidney transplant recipients
on mycophenolate while also demonstrating a dose effect
with reduced seroresponse rates in those receiving X2 g per
day compared with o2 g per day. Sanchez-Fructuoso et al.12
did not see a difference in seroprotection rates at 1 month
post vaccination in patients taking mycophenolate compared
with those taking azathioprine, but there was a 50% lower
rate of seroprotection in those on mycophenolate at 3
months post vaccination. Similarly, in three recent studies
using adjuvanted pH1N1 vaccination, the mean myco-
phenolate dose was higher in non-responders compared
with responders in one study;17 a second study described
higher trough levels in non-responders albeit not statistically
significant,19 whereas the third demonstrated suppressed
mean antibody titers in mycophenolate-treated compared
with azathioprine-treated patients.18 Mycophenolate inhibits
both T- and B-cell proliferation by depleting guanosine
nucleotides through inhibition of the enzyme inosine
monophosphate dehydrogenase, which is expressed prefer-
entially in activated lymphocytes.24 This mechanism differs
from that of azathioprine and may contribute to differences
in antibody responses. Taken together, this collection of
data, strengthened by this study, indicates an independent
and dose-dependent effect of mycophenolate on antibody
responses to adjuvanted and non-adjuvanted influenza
vaccination.
Reduced eGFR modified the probability of achieving
seroprotection in kidney transplant recipients without base-
line seroprotection. In all, 90% of healthy controls (no renal
disease) without baseline seroprotection achieved seroprotec-
tion post vaccination. There was a stepwise decrease in the
likelihood of achieving seroprotection in kidney transplant
recipients based on their renal function, with 45% of those
with satisfactory kidney graft function (eGFR 460ml/min
per 1.73m2), 35% with intermediate kidney function (eGFR
30–60ml/min per 1.73m2), and only 15% with poor kidney
function (o30ml/min per 1.73m2) achieving seroprotec-
tion. Immunosuppression therefore appears to halve the odds
of achieving seroprotection in transplant recipients with
excellent kidney function. Worsening allograft function
appears to further suppress immune responses. Given that
the hemodialysis patients achieved seroprotection rates equi-
valent to the transplant recipients with eGFR 460ml/min
per 1.73m2, a possible approximate equivalence of the
effects of renal failure and immunosuppression on vaccine
responses is suggested, with the combination of both renal
failure and immunosuppression being additive. In addition,
older age and shorter transplant duration were statistically
significant associates of a lower likelihood of achieving
seroprotection in a multivariate analysis in the transplant
recipients. Although studies including larger numbers of
participants are required to confirm a suppressive effect of
rituximab on seroresponses to vaccination, B-cell depletion
would be anticipated to limit the generation of plasma cells
specific for new antigens.
The value of booster dosing in renal transplant recipients
on modern immunosuppression is unclear. Scharpe et al.13
did not see an increase in seroprotection or seroresponses in
patients given a second dose of a trivalent influenza vaccine 3
months after the initial dose; however, their patient cohort
had an exceptionally high baseline level of seroprotection,
which the authors suggest is likely the result of their annual
vaccination policy, thereby mitigating the argument that
booster dosing is ineffective. Brakemeier et al.17 describe one
additional patient attaining seroprotection against pH1N1
after a booster dose of an adjuvanted vaccine 21 days after the
first and conclude that booster dosing is ineffective; however,
only 19 patients were studied. Our results demonstrate a
potentially important increment in the rate of seroprotection
and geometric mean titers with booster dosing. Although the
previous studies examined boosting with the same vaccine
within the same season, this study examines the boosting
effect of revaccination with a different vaccine after a longer
interval period, which may have contributed to the observed
differences in results. Our data suggest that annual vaccina-
tion will generate an increased rate of protection in a cohort
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of transplant recipients against antigens commonly repre-
sented in seasonal influenza vaccines, thereby supporting
current recommendations. The optimal timing and frequency
of booster dosing remains unclear. In addition, although
boosting may increase seroprotection against known influ-
enza strains without crossreactivity against future novel
influenza variants, pandemics will not be prevented.
This study is strengthened by the inclusion of a large
cohort of kidney transplant recipients with low baseline
seroprotection, allowing a more detailed analysis of factors
influencing seroresponses than previous vaccine studies.
Inclusion of both hemodialysis patients and healthy controls
is novel and has allowed demonstration of a hierarchy of
seroresponses in renal failure patients. Study limitations
include the following: the predominance of mycophenolate
use in the kidney transplant recipients, which limited
numbers in the non-mycophenolate group and restricted
subanalyses, and that only 1/3 of our transplant recipient
cohort took part in the study, which may have resulted in
exclusion of an important subgroup of patients.
We have demonstrated that the pH1N1 monovalent
vaccine, although highly effective at producing seroprotective
antibody titers in healthy individuals, has significantly
reduced efficacy at standard dosing in hemodialysis patients
and particularly in kidney transplant recipients. Nevertheless,
a significant proportion of patients achieved protective
antibody titers with excellent safety outcomes. Kidney
transplant recipients taking mycophenolate and those with
poor allograft function had the lowest likelihood of achieving
seroprotection. Repeat vaccination increased seroprotection
rates, supporting the current recommendation for annual
influenza vaccination of renal transplant recipients.
MATERIALS AND METHODS
Study design and setting
This is a prospective cohort study, assessing seroresponses to the
monovalent pH1N1 vaccine in kidney transplant recipients and
hemodialysis patients within the Department of Nephrology,
Monash Medical Centre, Melbourne, Victoria, Australia.
Study population
From October to December 2009, we attempted to contact all
kidney transplant recipients (n¼ 526) by post and/or phone or to
offer vaccination with the monovalent pH1N1 vaccine (Figure 1).
All kidney transplant recipients were potentially eligible for
inclusion in the study. Subjects were excluded if they had received
the monovalent pH1N1 vaccine previously, had been transplanted
o21 days before vaccination, or had a known allergy to the
influenza vaccine, eggs, and/or chicken products. All hemodialysis
patients treated in two community dialysis facilities were also
approached and offered vaccination with the monovalent pH1N1
vaccine (n¼ 82). Pre- and post-vaccination sera from a cohort of 30
healthy controls who received the monovalent pH1N1 vaccine were
kindly provided by CSL Limited (Parkville, Victoria, Australia) and
served as a comparison set of samples to sera from kidney transplant
recipients and hemodialysis patients. Patients consented to receive
the monovalent pH1N1 vaccine, and their de-identified data were
used to audit seroresponses.
For the boosting study, we recontacted all our kidney transplant
recipients in May 2010 and recommended that they receive the 2010
trivalent influenza vaccine. Of the original 151 transplant recipients,
49 who received the monovalent pH1N1 vaccine received the 2010
trivalent influenza vaccine and had their antibody titers repeated.
Data collection and measures
Patients attended outpatient vaccination clinics wherein they
received a single 15 mg intramuscular dose of the monovalent
unadjuvanted, split-virus pH1N1 vaccine (Panvax H1N1, CSL
Biotherapies, Parkville, Victoria, Australia). Pre- and 1 month
post-vaccination sera were collected. Kidney transplant recipients in
the boosting study received a single intramuscular dose of a 2010
trivalent inactivated unadjuvanted split-virus vaccine containing
15 mg of A/California/7/2009 (H1N1-like) antigen and had antibody
titers measured at a median of 56.5 days (range 27–178 days) post
vaccination.
Antibody titers for pH1N1 were measured using hemagglutina-
tion inhibition assays at the WHO Collaborating Centre for
Reference and Research on Influenza in Melbourne, using methods
described previously.4 Briefly, sera were pretreated by combining 1
part of serum with 4 parts of receptor-destroying enzyme II (Denka
Seiken, Tokyo, Japan) (volume/volume) and incubation at 37 1C for
12 h, followed by the addition of 5 parts of 1.6% sodium citrate and
incubation at 56 1C for 30min. Egg-grown A/California/7/2009
virus was purified by sucrose gradient, concentrated and inactivated
with b-propiolactone (kindly provided by CSL Limited), and diluted
to 4 hemagglutinating units/25 ml. Following a 1-h incubation of
virus and antisera, 25 ml of 1% (volume/volume) turkey red blood
cells was added to each well, and the hemagglutination inhibition
was read after 30min of incubation. Titers were expressed as the
reciprocal of the highest dilution of serum where hemagglutination
was prevented.
Subject demographics, comorbidity, cause of end-stage kidney
disease, and medication use including current and previous
immunosuppressive drug regimen was assessed at the time of
vaccination. Kidney function was assessed by the eGFR, calculated
using the 4-variable IDMS traceable MDRD study equation. Serum
25-hydroxy vitamin D levels were also obtained before vaccination.
Study outcomes
Seroprotection was defined as having an anti-pH1N1 titer of X40.
Seroconversion was defined as having an anti-pH1N1 titer of X40
and a rise in antibody titer of X4 times the pre-vaccination level.
Statistical methods
Univariate associations between antibody responses in the three
groups were explored using analysis of variance or Kruskal–Wallis
rank test for continuous variables and the w2 test or Fisher’s exact
test for categorical variables where appropriate. Geometric means of
antibody titers were also calculated (sera with a titer of o10 were
recorded as 5).
Multivariate logistic regression was used to assess factors
associated with an increased likelihood of seroconversion or
seroprotection following vaccination with the monovalent pH1N1
vaccine, including female gender, subject age, hemodialysis or
kidney transplant recipient, kidney transplant age, immunosup-
pressive regimen (calcineurin inhibitor, mycophenolate, steroid, and
rituximab use), and transplant function. Models were built using
backward stepwise elimination of covariates, using Wald tests and a
threshold of 0.10 for retention. Any clinically important factors
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(regardless of statistical significance) were kept in the final model.
We declared a finding to be statistically significant if the two-sided
P-value was o0.05. All analyses were conducted on Stata 11.2
(StataCorp, College Station, TX).
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